SEOUL, South Korea, Nov. 28, 2017 -- ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced a poster presentation on its CRISPR technology at the upcoming American Society of Hematology (ASH) Annual Meeting, being held December 9-12 in Atlanta, Georgia.
The poster presentation entitled “CRISPR/Cas9-Mediated Diacylglycerol Kinase Knockout Potentiates Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T-Cells” will cover a study that explored a potential solution to tumors evading immune surveillance by deactivating T cells. Researchers strengthened T cell function by deleting Diacylglycerol kinase (DGKs) using CRISPR/Cas9. The study found that the observed biological effects may also yield new strategies for improving the efficacy of T-cell therapy in combination with signal 2 checkpoint inhibitors in clinical applications.
Details of the presentation are below:
| Poster: | 3182 - CRISPR/Cas9-Mediated Diacylglycerol Kinase Knockout Potentiates Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T-Cells | |
| Lead Author: | In-Young Jung, MS | |
| Poster Session: | 703: Adoptive Immunotherapy: Poster II | |
| Date: | Sunday, December 10, 2017 | |
| Time: | 6:00 - 8:00pm CT | |
| Location: | Georgia World Congress Center Building A, Level 1, Hall A2 |
About ToolGen, Inc.
ToolGen, Inc. is a biotechnology company focused on the development and application of genome editing technologies. It creates and holds intellectual property rights for essential tools and technologies for editing the genetic information in microbial, plant, animal, and human cells. ToolGen’s mission is to translate the potential of its innovative platform technology into transformative products for biomedicine and agriculture. For more information, please visit www.toolgen.com.
Contacts
Company – Seokjoong Kim +82-2-873-8168
Media – Kirsten Thomas (508) 280-6592
Investors – Tram Bui (646) 536-7035
